Results 211 to 220 of about 15,072 (244)
Some of the next articles are maybe not open access.
Current opinion in investigational drugs (London, England : 2000), 2003
Pharmacia Corp (formerly GD Searle & Co) is developing eplerenone, an aldosterone receptor antagonist, as a potential treatment for congestive heart failure and systemic hypertension. The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on ...
Liew, Danny +2 more
openaire +1 more source
Pharmacia Corp (formerly GD Searle & Co) is developing eplerenone, an aldosterone receptor antagonist, as a potential treatment for congestive heart failure and systemic hypertension. The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on ...
Liew, Danny +2 more
openaire +1 more source
▼Eplerenone after myocardial infarction?
Drug and Therapeutics Bulletin, 2008Each year in the UK, an estimated 50,000 patients develop major left ventricular systolic dysfunction (LVSD) and heart failure following a myocardial infarct.1 Such patients have a particularly poor prognosis.2 ▼Eplerenone (Inspra – Pfizer) is an aldosterone-receptor antagonist for patients who have LVSD and heart failure following a recent myocardial ...
openaire +2 more sources